News | August 22, 2014

Physicians Implant World's First ProMRI Quadripolar CRT-D System

Patients receive new Biotronik cardiac resynchronization therapy implantable defibrillators that grant MRI access and reduce shocks

August 22, 2014 — Biotronik announced the first implantations worldwide of its new ICD and CRT-D series (implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators). With Sentus quadripolar leads and the Inventra series, Biotronik offers the only devices for patients with heart failure worldwide that are approved for magnetic resonance imaging (MRI) use. The quadripolar Sentus lead eases the implantation process by giving physicians access to challenging vessels. With CE approval in early July, Biotronik’s new implantable defibrillator series includes the industry’s first quadripolar left-ventricular leads to be approved for MRI use.

Biotronik is the first and only company to offer heart failure patients cardiac resynchronization therapy devices and leads that can undergo MRI scans. As patients age, they may develop comorbidities, and MRI scans can be critical in diagnosing conditions like stroke, brain tumors or orthopedic conditions.

“My ICD and heart failure patients are frequently indicated for MRI scans to diagnose potential comorbidities,” commented Dr. Antonio Curnis, Spedali Civili Hospital, Brescia, Italy, who implanted a new Biotronik ProMRI Inventra HF-T and Sentus quadripolar lead in a 73-year-old patient with congestive heart failure. “With Biotronik devices, I know I can give my patients high-quality therapy and broad access to diagnostics.”

In addition to ProMRI technology, the new Biotronik ICDs and CRT-Ds reduce inappropriate shocks with MorphMatch morphology detection criteria and anti-tachycardia pacing (ATP) optimization. While delivering shocks at the right time can save patients' lives, shocks should be minimized to appropriately control arrhythmias, improve patients' quality of life and increase device longevity.

Dr. Werner Jung, Schwarzwald-Baar Clinic, Villingen Schwenningen, Germany, successfully implanted a 72-year-old heart failure patient with a new ProMRI CRT-D from Biotronik. “Biotronik has proved the exceptional quality of its products once again with the new ICDs and Sentus quadripolar leads,” commented Jung. "Many heart failure patients are very ill and shocks put stress on the body and mind. By choosing a device with unique algorithms that reduce shocks, I am able to give my patients peace of mind and restore their sense of safety.”

Biotronik has included its Closed Loop Stimulation (CLS) technology in ICDs for the first time. CLS helps patients experience the most natural rate adoption possible by utilizing their neurological information. It is the only system that allows pacemakers, and now ICDs, to react naturally to patients’ physical as well as mental activity or stress.

For more information: www.biotronik.com

Related Content

Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...
Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT) | May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
Overlay Init